GC Biopharma announced on August 17, 2023 that it has presented the results of analyzing and comparing thrombotic adverse events of Hemlibra and Factor FVIII replacements reported in the US Food and Drug Administration Adverse Event Reporting System at the Bleeding Disorder Conference currently being held in Maryland, U.S. from August 17 to August 19, 2023.
